VIA EDGAR
December 10, 2019
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: | Jeffrey Gabor, Office of Life Sciences |
|
|
Re: | Spring Bank Pharmaceuticals, Inc. |
| Registration Statement on Form S-3 |
| File No. 333-234436 |
| Request for Acceleration
|
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Spring Bank Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-234436) (the “Registration Statement”), so that it may become effective at 4:00 p.m. (Washington, D.C. time) on Thursday, December 12, 2019, or as soon as practicable thereafter.
Please call Megan N. Gates (617-348-4443) of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, with any comments or questions regarding this matter.
Very truly yours,
Spring Bank Pharmaceuticals, Inc.
By: /s/ Jonathan Freve
Jonathan Freve
Chief Financial Officer
